CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
Acalabrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04380688
NCT04380688Phase 2Completed
CompareCT.gov

A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19

AstraZeneca·interventional·Posted May 8, 2020·Updated Sep 13, 2021

In Brief

A Phase 2 clinical trial evaluating Acalabrutinib for COVID-19. Completed, enrolled 62 participants across 31 sites.

Detailed Summary

CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsAcerta Pharma BV

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 8, 2020
Enrollment StartJun 13, 2020
Primary CompletionNov 16, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.1 years ago

Interventions

Acalabrutinibdrug

Acalabrutinib administered orally